Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May-Jun;15(3):1001-1006.
doi: 10.1016/j.dsx.2021.05.008. Epub 2021 May 7.

Elucidating reasons of COVID-19 re-infection and its management strategies

Affiliations
Review

Elucidating reasons of COVID-19 re-infection and its management strategies

Vijay Kumar Jain et al. Diabetes Metab Syndr. 2021 May-Jun.

Abstract

Background and aims: Reinfection is gradually being recognised after symptomatic or asymptomatic COVID-19 infection. We try to elucidate various explanations behind COVID-19 reinfection and suggest possible strategies to counteract this threat.

Methods: We carried out a comprehensive review of the literature using suitable keywords such as 'COVID-19', 'Pandemics', 'Reinfection', 'Vaccines' and 'India' on the search engines of PubMed, SCOPUS, Google Scholar and Research Gate in March 2021 and first half of April 2021 during the current COVID-19 pandemic. Epidemiology, risk factors and trends of reinfection were assessed.

Results: A multitude of factors have been associated with rising incidence of COVID-19 reinfection in India and across the world. Emergence of 'Variants of Concern (VOC)', pandemic fatigue and disregard of infection prevention strategies appear to be the most obvious reasons.

Conclusions: COVID-19 reinfection is an emerging concern amongst the worldwide population with newer mutant strains demonstrating increasing transmissibility and responsible for continuing waves of the pandemic. COVID Appropriate Behaviour (CAB), improvised vaccines and enhanced vaccination drives are necessary to mitigate global threat.

Keywords: COVID-19; Pandemics; Reinfection; Risk compensation; SARS-CoV-2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None declared.

Similar articles

Cited by

References

    1. Elzein F., Ibrahim A., Alshahrani F., Mahrous M., Murshid E., Aldhehyan T., Almutiri G., Altowairqi M., Ahmed M., Alsaeed M., Alsufyani E., Alnawshan N. Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature. J Infect Public Health. 2021 Apr;14(4):474–477. doi: 10.1016/j.jiph.2021.01.002. Epub 2021 Jan 14. - DOI - PMC - PubMed
    1. Sharma R., Sardar S., Mohammad Arshad A., Ata F., Zara S., Munir W. A patient with asymptomatic SARS-CoV-2 infection who presented 86 Days later with COVID-19 pneumonia possibly due to reinfection with SARS-CoV-2. Am J Case Rep. 2020 Dec 1;21 doi: 10.12659/AJCR.927154. - DOI - PMC - PubMed
    1. Azam M., Sulistiana R., Ratnawati M., Fibriana A.I., Bahrudin U., Widyaningrum D., Aljunid S.M. Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis. Sci Rep. 2020 Nov 26;10(1):20692. - PMC - PubMed
    1. Mattiuzzi C., Henry B.M., Sanchis-Gomar F., Lippi G. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta Biomed. 2020 Sep 7;91(3) - PMC - PubMed
    1. Shoar S., Khavandi S., Tabibzadeh E., Khavandi S., Naderan M., Shoar N. Recurrent coronavirus diseases 19 (COVID-19): a different presentation from the first episode. Clin Case Rep. 2021 Feb 23 doi: 10.1002/ccr3.3967. - DOI - PMC - PubMed

Substances